External link, please review our disclaimer.

NIDA Funding Strategy for Fiscal Year 2009

Based on the enacted Omnibus appropriation, the National Institute on Drug Abuse (NIDA) has established the following funding policy.

New and Competing (Type 1 & 2)

New and competing grants will be funded at a 3% increase over FY 2008.

Non-competing Continuations (Type 5)

New Investigators

  • NIDA is committed to supporting first-time R01 investigators and Early Stage Investigators (by NIH definition). This means new investigator status will be considered in funding decisions and is one factor in funding grants beyond the normal payline. For the policy on New and Early Stage Investigators go to http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-013.html.

Ruth L. Kirschstein National Research Service Awards (NRSA)

NIH has established new increased stipend levels for fiscal year 2009 NRSA awards. For more information visit http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-075.html

Search for Funding

Featured Publication

Mentoring, A Guide for Drug Abuse Researchers publication cover

Mentoring: A Guide for Drug Abuse Researchers

Discusses the importance of quality mentorship in drug abuse research and offers suggestions for creating a successful mentor and mentee relationship.

The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH), a component of the U.S. Department of Health and Human Services. NIH...Turning Discovery Into Health

National Institute on Drug Abuse   |   6001 Executive Boulevard, Room 5213   |   Bethesda, MD 20892-9561

Questions for our staff? E-mail information@nida.nih.gov or call 301-443-1124 (240-221-4007 en español).

Mobile Site